Skip to content

Effect of roxadustat in peritoneal dialysis patients with erythropoietin hyporesponsiveness: A real-world 16-week study

Effect of roxadustat in peritoneal dialysis patients with erythropoietin hyporesponsiveness: A real-world 16-week study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300076409
Enrollment
Unknown
Registered
2023-10-08
Start date
2023-06-01
Completion date
Unknown
Last updated
2023-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Peritoneal dialysis

Interventions

Sponsors

The Second Affiliated Hospital of Xuzhou Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) The patients were aged between 18 and 75 years old; (2) Patients with CKD associated with renal anemia underwent regular PD for more than 12 weeks.

Exclusion criteria

Exclusion criteria: (1) Patients who were transferred to HD, kidney transplantation during the follow-up period; (2) Patients with other diseases causing anemia during the follow-up period, such as hematological disorders, hemorrhagic diseases resulting from various causes, and so on; (3) Patients who took other drugs for anemia or underwent blood transfusion during the follow-up period; (4) Patients with other serious chronic diseases, such as severe liver function impairment, severe heart failure, malignancy, serious infections, malignant hypertension.

Design outcomes

Primary

MeasureTime frame
Hemoglobin;Total cholesterol;Parathyroid hormone;Brain natriuretic peptide ;Left ventricular ejection fraction;Cardiovascular event;

Countries

China

Contacts

Public ContactXinglei Zhou

The Second Affiliated Hospital of Xuzhou Medical University

dzhouxinglei@163.com+86 188 5218 1458

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026